Key result
Liposomal adriamycin combined with rTNF-alpha significantly improved therapeutic effects on tumor growth and increased Adriamycin levels in tumor tissue compared to monotherapy or saline in mice.
Why the study?
Does liposomal adriamycin in combination with rTNF-alpha improve tumor growth reduction in nude mice bearing human colon cancer?
Does liposomal adriamycin in combination with rTNF-alpha improve tumor growth reduction in nude mice bearing human colon cancer?
Pretreatment with rTNF-alpha enhances the therapeutic efficacy and tumor tissue accumulation of liposomal adriamycin in a mouse model of human colon cancer.
Should not yet change clinical practice; hypothesis-generating for rTNF-alpha pretreatment with liposomal adriamycin in colon cancer models.
Liposomes as drug carriers in cancer chemotherapy have attracted considerable interest. To enhance the therapeutic effect of Adriamycin entrapped in liposomes (Lip-ADM) on human solid tumors, we investigated the therapeutic effects of Lip-ADM in combination with recombinant human tumor necrosis factor-alpha (rTNF-alpha), which is known to have specific effects on tumor vasculature. rTNF-alpha or saline solution was injected intravenously into nude mice bearing a human colon cancer strain, HC-1, at 1 hour before intravenous administration of Lip-ADM. The significant therapeutic effect of Lip-ADM in combination with rTNF-alpha was demonstrated by the evaluation with tumor growth curve and the actual tumor weights, in comparison with groups of mice treated with saline solution, rTNF-alpha alone, or with a Lip-ADM after saline. Levels of Adriamycin in tumor tissue in the Lip-ADM in combination with rTNF-alpha-treated group were higher than those in Lip-ADM with saline solution-treated group.
No takes yet. Share an insight, caveat, or question.
Maruo et al. (1992) studied Human colon cancer (HC-1 strain) in nude mice. Liposomal adriamycin (Lip-ADM) in combination with recombinant human tumor necrosis factor-alpha (rTNF-alpha) vs. Saline solution, rTNF-alpha alone, or Lip-ADM after saline was evaluated on Tumor growth curve, actual tumor weights, and levels of Adriamycin in tumor tissue. Liposomal adriamycin combined with rTNF-alpha significantly improved therapeutic effects on tumor growth and increased Adriamycin levels in tumor tissue compared to monotherapy or saline in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: